FYERS
Home
/
Stocks
/
Results
/
Hester Biosciences Results

Hester Biosciences Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
13%9%8%7%
11%10%28%99%
11%-2%10%13%
16%12%11%17%

Peer Comparison

Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
MANKIND
DRREDDY
AUROPHARMA
LUPIN
HESTERBIO
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,849.9₹447476 Cr3712.0762.82₹11479 Cr
9,602₹254764 Cr87.134.04128.41₹2568 Cr
4,928.5₹189423 Cr86.8516.7297.06₹2163 Cr
1,180.3₹116658 Cr25.859.4262.53₹5040 Cr
1,399₹111484 Cr33.089.7757.87₹3879 Cr
2,026.2₹109943 Cr100.556.829.25₹889 Cr
2,500₹101712 Cr49.7913.7571.08₹1913 Cr
1,200.4₹101005 Cr31.355.3263.99₹4196 Cr
1,716₹99253 Cr26.7317.9596.84₹3505 Cr
2,100.7₹96031 Cr17.3730.95154.35₹5333 Cr
2,196₹1911 Cr14.03114185.64₹56 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%

Balance Sheet

Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Less Impairment of Assets
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015Mar 2014Mar 2013Mar 2012Mar 2011
————————————————
₹9 Cr₹9 Cr₹9 Cr₹9 Cr₹9 Cr₹9 Cr₹9 Cr₹9 Cr₹9 Cr₹9 Cr₹9 Cr₹9 Cr₹9 Cr₹9 Cr₹6 Cr₹5 Cr
₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹2 Cr
₹352 Cr₹306 Cr₹283 Cr₹271 Cr₹251 Cr₹220 Cr₹193 Cr₹169 Cr₹132 Cr₹113 Cr₹93 Cr₹76 Cr₹67 Cr₹59 Cr₹54 Cr₹41 Cr
₹352 Cr₹306 Cr₹283 Cr₹271 Cr₹251 Cr₹220 Cr₹193 Cr₹169 Cr₹132 Cr₹113 Cr₹93 Cr₹76 Cr₹67 Cr₹59 Cr₹54 Cr₹41 Cr
₹360 Cr₹314 Cr₹292 Cr₹280 Cr₹260 Cr₹228 Cr₹201 Cr₹177 Cr₹141 Cr₹122 Cr₹102 Cr₹85 Cr₹75 Cr₹67 Cr₹60 Cr₹48 Cr
₹8 Cr₹12 Cr₹11 Cr₹9 Cr₹7 Cr₹8 Cr₹5 Cr₹4 Cr₹4 Cr₹5 Cr₹5 Cr₹3 Cr₹1 Cr₹1 Cr₹1 Cr₹64 L
₹90 Cr₹133 Cr₹182 Cr₹185 Cr₹165 Cr₹83 Cr₹76 Cr₹58 Cr₹37 Cr₹45 Cr₹33 Cr₹31 Cr₹15 Cr₹14 Cr₹1 Cr₹4 Cr
₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹90 L₹76 L₹0₹0₹0
₹9 Cr₹6 Cr₹7 Cr₹7 Cr₹7 Cr₹7 Cr₹9 Cr₹11 Cr₹8 Cr₹4 Cr₹8 Cr₹5 Cr₹5 Cr₹3 Cr₹2 Cr₹3 Cr
₹57 Cr₹59 Cr₹62 Cr₹39 Cr₹26 Cr₹24 Cr₹11 Cr₹62 L₹5 L₹15 L₹15 L₹54 L₹1 L₹0₹2 Cr₹0
₹2 Cr₹3 Cr₹3 Cr₹2 Cr₹1 Cr₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0
₹158 Cr₹202 Cr₹254 Cr₹233 Cr₹198 Cr₹114 Cr₹97 Cr₹70 Cr₹44 Cr₹48 Cr₹41 Cr₹38 Cr₹20 Cr₹16 Cr₹6 Cr₹6 Cr
————————————————
₹25 Cr₹29 Cr₹26 Cr₹30 Cr₹18 Cr₹28 Cr₹20 Cr₹9 Cr₹8 Cr₹7 Cr₹6 Cr₹5 Cr₹5 Cr₹6 Cr₹4 Cr₹3 Cr
₹97 Cr₹61 Cr₹45 Cr₹56 Cr₹43 Cr₹23 Cr₹30 Cr₹17 Cr₹20 Cr₹11 Cr₹9 Cr₹6 Cr₹7 Cr₹9 Cr₹4 Cr₹5 Cr
₹24 Cr₹30 Cr₹31 Cr₹59 Cr₹35 Cr₹3 Cr₹33 Cr₹22 Cr₹25 Cr₹18 Cr₹21 Cr₹20 Cr₹30 Cr₹16 Cr₹13 Cr₹15 Cr
₹7 Cr₹5 Cr₹3 Cr₹4 Cr₹1 Cr₹7 Cr₹46 L₹26 L₹1 Cr₹1 Cr₹2 Cr₹4 Cr₹4 Cr₹8 Cr₹7 Cr₹5 Cr
₹152 Cr₹125 Cr₹105 Cr₹149 Cr₹97 Cr₹61 Cr₹83 Cr₹49 Cr₹55 Cr₹38 Cr₹38 Cr₹35 Cr₹45 Cr₹39 Cr₹28 Cr₹28 Cr
₹678 Cr₹653 Cr₹662 Cr₹670 Cr₹562 Cr₹411 Cr₹387 Cr₹299 Cr₹244 Cr₹213 Cr₹186 Cr₹160 Cr₹142 Cr₹124 Cr₹95 Cr₹82 Cr
₹0₹0₹0₹20 L₹15 L₹15 L₹11 L₹11 L₹67 L₹62 L₹62 L₹56 L₹0₹12 Cr₹3 Cr₹19 L
₹188 Cr₹208 Cr₹239 Cr₹268 Cr₹223 Cr₹105 Cr₹121 Cr₹90 Cr₹69 Cr₹66 Cr₹59 Cr₹55 Cr₹48 Cr₹32 Cr₹16 Cr₹21 Cr
————————————————
₹585 Cr₹390 Cr₹382 Cr₹386 Cr₹348 Cr₹228 Cr₹226 Cr₹216 Cr₹170 Cr₹153 Cr₹108 Cr₹98 Cr₹87 Cr₹65 Cr₹62 Cr₹58 Cr
₹174 Cr₹157 Cr₹142 Cr₹126 Cr₹111 Cr₹95 Cr₹83 Cr₹71 Cr₹60 Cr₹50 Cr₹44 Cr₹38 Cr₹33 Cr₹28 Cr₹23 Cr₹19 Cr
₹0₹0₹0₹0₹0₹0₹0₹14 L₹0₹0₹0₹0₹0₹0₹0₹0
₹411 Cr₹233 Cr₹240 Cr₹259 Cr₹237 Cr₹133 Cr₹143 Cr₹145 Cr₹110 Cr₹103 Cr₹65 Cr₹60 Cr₹54 Cr₹38 Cr₹39 Cr₹39 Cr
₹0₹177 Cr₹168 Cr₹146 Cr₹80 Cr₹109 Cr₹74 Cr₹7 Cr₹32 Cr₹21 Cr₹36 Cr₹33 Cr₹21 Cr₹29 Cr₹6 Cr₹4 L
₹43 Cr₹34 Cr₹30 Cr₹25 Cr₹21 Cr₹0₹0₹0₹0₹0₹7 L₹28 L₹28 L₹28 L₹0₹0
₹43 Cr₹34 Cr₹30 Cr₹25 Cr₹21 Cr₹0₹0₹0₹0₹0₹7 L₹28 L₹28 L₹28 L₹0₹0
₹6 Cr₹7 Cr₹6 Cr₹8 Cr₹24 Cr₹5 Cr₹7 Cr₹4 Cr₹3 Cr₹9 Cr₹10 Cr₹8 Cr₹10 Cr₹7 Cr₹4 Cr₹5 Cr
₹49 L₹2 Cr₹74 L₹1 Cr₹3 Cr₹3 Cr₹4 Cr₹2 Cr₹8 L₹47 L₹0₹0₹0₹0₹0₹0
₹469 Cr₹458 Cr₹448 Cr₹442 Cr₹367 Cr₹250 Cr₹227 Cr₹158 Cr₹146 Cr₹133 Cr₹112 Cr₹100 Cr₹85 Cr₹74 Cr₹49 Cr₹44 Cr
————————————————
₹73 Cr₹70 Cr₹76 Cr₹85 Cr₹75 Cr₹62 Cr₹64 Cr₹51 Cr₹40 Cr₹33 Cr₹34 Cr₹29 Cr₹36 Cr₹31 Cr₹28 Cr₹23 Cr
₹95 Cr₹73 Cr₹79 Cr₹80 Cr₹55 Cr₹49 Cr₹58 Cr₹33 Cr₹32 Cr₹27 Cr₹26 Cr₹18 Cr₹14 Cr₹15 Cr₹14 Cr₹13 Cr
₹7 Cr₹7 Cr₹15 Cr₹15 Cr₹25 Cr₹21 Cr₹24 Cr₹41 Cr₹13 Cr₹11 Cr₹5 Cr₹7 Cr₹5 Cr₹3 Cr₹4 Cr₹2 Cr
₹7 Cr₹8 Cr₹6 Cr₹6 Cr₹5 Cr₹3 Cr₹5 Cr₹6 Cr₹4 Cr₹3 Cr₹7 Cr₹0₹0₹0₹0₹0
₹27 Cr₹37 Cr₹39 Cr₹42 Cr₹34 Cr₹26 Cr₹8 Cr₹11 Cr₹9 Cr₹5 Cr₹2 Cr₹7 Cr₹3 Cr₹1 Cr₹50 L₹70 L
₹209 Cr₹195 Cr₹215 Cr₹228 Cr₹195 Cr₹162 Cr₹159 Cr₹142 Cr₹98 Cr₹80 Cr₹74 Cr₹60 Cr₹57 Cr₹50 Cr₹46 Cr₹38 Cr
₹56 Cr₹70 Cr₹109 Cr₹79 Cr₹98 Cr₹100 Cr₹76 Cr₹93 Cr₹44 Cr₹42 Cr₹36 Cr₹25 Cr₹12 Cr₹11 Cr₹18 Cr₹10 Cr
₹678 Cr₹653 Cr₹662 Cr₹670 Cr₹562 Cr₹411 Cr₹387 Cr₹299 Cr₹244 Cr₹213 Cr₹186 Cr₹160 Cr₹142 Cr₹124 Cr₹95 Cr₹82 Cr
₹423₹369₹343₹329₹306₹268₹236₹209₹165₹143₹120₹100₹88₹79₹105₹89
₹423₹369₹343₹329₹306₹268₹236₹209₹165₹143₹120₹100₹88₹79₹70₹59

Cash Flow

Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Cash & Cash Equivalent of Subsidiaries under liquidations
Effect of Foreign Exchange Fluctuations
Closing Cash & Cash Equivalent
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015Mar 2014Mar 2013Mar 2012Mar 2011
₹76 Cr₹40 Cr₹32 Cr₹40 Cr₹54 Cr₹50 Cr₹41 Cr₹57 Cr₹36 Cr₹31 Cr₹25 Cr₹18 Cr₹13 Cr₹14 Cr₹12 Cr₹11 Cr
₹34 Cr₹26 Cr₹24 Cr₹12 Cr₹11 Cr₹20 Cr₹20 Cr₹18 Cr₹14 Cr₹11 Cr₹9 Cr₹7 Cr₹12 Cr₹8 Cr₹7 Cr₹7 Cr
-₹31 Cr₹10 Cr₹4 Cr-₹21 Cr-₹39 Cr₹2 Cr-₹14 Cr-₹12 Cr-₹2 Cr₹11 L-₹9 Cr-₹33 L-₹6 Cr-₹5 Cr-₹4 Cr-₹10 Cr
₹78 Cr₹76 Cr₹60 Cr₹32 Cr₹26 Cr₹72 Cr₹48 Cr₹63 Cr₹47 Cr₹42 Cr₹25 Cr₹25 Cr₹19 Cr₹17 Cr₹15 Cr₹8 Cr
₹64 Cr₹65 Cr₹48 Cr₹24 Cr₹9 Cr₹58 Cr₹37 Cr₹47 Cr₹38 Cr₹35 Cr₹19 Cr₹20 Cr₹9 Cr₹12 Cr₹14 Cr₹5 Cr
-₹3 Cr-₹19 Cr-₹23 Cr-₹77 Cr-₹117 Cr-₹38 Cr-₹74 Cr-₹22 Cr-₹26 Cr-₹30 Cr-₹13 Cr-₹21 Cr-₹15 Cr-₹23 Cr-₹10 Cr-₹4 Cr
-₹49 Cr-₹52 Cr-₹26 Cr₹42 Cr₹112 Cr-₹18 Cr₹19 Cr₹3 Cr-₹11 Cr₹2 Cr-₹7 Cr₹7 Cr₹7 Cr₹10 Cr-₹2 Cr-₹81 L
₹12 Cr-₹6 Cr-₹52 L-₹12 Cr₹4 Cr₹1 Cr-₹19 Cr₹28 Cr₹1 Cr₹6 Cr-₹1 Cr₹5 Cr₹2 Cr-₹1 Cr₹2 Cr₹64 L
₹6 Cr₹12 Cr₹13 Cr₹25 Cr₹21 Cr₹24 Cr₹41 Cr₹12 Cr₹11 Cr₹5 Cr₹6 Cr₹82 L₹2 Cr₹3 Cr₹1 Cr₹96 L
-₹42 L₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0
₹0₹0₹0₹0₹0₹0₹0₹69 L₹3 L₹0₹0₹0₹0₹0₹0₹0
-₹15 Cr-₹51 L₹16 L₹5 L-₹18 L-₹4 Cr₹2 Cr₹0₹0₹0₹0-₹68,842₹0₹0₹0₹0
₹3 Cr₹6 Cr₹12 Cr₹13 Cr₹25 Cr₹21 Cr₹24 Cr₹41 Cr₹12 Cr₹11 Cr₹5 Cr₹6 Cr₹4 Cr₹2 Cr₹3 Cr₹2 Cr

Fundamental Ratios

Consolidated
Standalone

Share Price Live Stats

Open (₹)2,237.80
Volume (₹)1,381.00
High (₹)2,237.90
Upper Circuit2,690.10
Low (₹)2,187.10
Lower Circuit1,793.50
Prev Close2,241.80
52W High (₹)2,683.60
Price2,196.00
52W Low (₹)1,239.30

Share Market Cap & Key Ratios Overview

M.Cap (₹)1910.85 Cr
Div. Yield (%)0.49
PE Ratio14.03
Debt to Equity0.52
Price to Book2.98
Book Value423.46
EPS (TTM)160.08
Face Value10.00
ROE (%)17.05

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
LUPINNSE
HESTERBIONSE
LTP
1W Low
1W High
Market cap (₹)
1849.9+12.6 (0.69%)
1832.20
1891.50
4,47,476Cr
9602+227 (2.42%)
9312.50
9740
2,54,764Cr
4928.5+88.5 (1.83%)
4848.50
5010
1,89,423Cr
1180.3+20.3 (1.75%)
1152.10
1190.60
1,16,658Cr
1399+4.5 (0.32%)
1364.50
1419
1,11,484Cr
2026.2+72.2 (3.69%)
1963.80
2055.30
1,09,943Cr
2500+199.3 (8.66%)
2303
2504.30
1,01,712Cr
1200.4+15.4 (1.30%)
1185
1222
1,01,005Cr
1716-18 (-1.04%)
1689.30
1740
99,253Cr
2100.7+17.7 (0.85%)
2080
2135
96,031Cr
2196+0.4 (0.02%)
2158.50
2261.20
1,911Cr

Hester Biosciences Ltd Annual Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹24.42Cr; with other income of ₹1.64Cr, profit before interest and tax came to ₹102.72Cr. Interest expense was ₹3.08Cr; PBT before exceptional items stood at ₹99.64Cr. Cost mix (full year): raw materials ₹86.37Cr; employee cost ₹62.67Cr; depreciation ₹7.04Cr; other expenses ₹54.47Cr. Basis: consolidated annual results.

Hester Biosciences Ltd Quaterly Results Key Takeaways

Hester Biosciences Ltd reported ₹77.24Cr total income from operations in Jun 2026, softer than ₹100.11Cr in Mar 2026 but higher than ₹84.11Cr in Jun 2025. Operating profit (before other income, interest and exceptional items) was ₹24.42Cr; with other income of ₹1.64Cr, profit before interest and tax came to ₹102.72Cr. Interest expense was ₹3.08Cr, taking profit before tax to ₹99.64Cr. After tax of ₹4.95Cr, profit after tax stood at ₹94.69Cr (vs ₹14.69Cr in Mar 2026 and ₹16.25Cr in Jun 2025).